PubMed Health⌕ Search

Biomedical subjects

N J Pickett

Publications and source records attributed to N J Pickett.

2 recordsLinked to original sources

Shared pharmacy services: a cost-effective programme for small hospitals.

A pilot project for shared pharmacy service was undertaken to investigate costs and benefits under an agreement established between University Hospital, London and South Huron Hospital, Exeter, Ontario. The programme involved the use of facsimile telecopiers to transmit direct copies of the physicians' orders to the Pharmacy Department at University Hospital where they were entered into the computerized pharmacy system. At South Huron Hospital therapy was initiated from floor stock while the drug, dispensed in unit-of-use packaging, was delivered to the Exeter Hospital by courier service. The shared service pharmacist visited South Huron Hospital once weekly for nursing orientations, inservice lectures, patient consultations, medical staff meetings and direct contact with physicians. With the approval of the Bureau of Dangerous Drugs the pharmacist delivered Narcotic and Schedule G medications once weekly. After three months the patient census and average number of medication orders per patient per day had increased. The hours of pharmacy operation were extended, while the medication costs per patient day were reduced from $2.16 to $1.64. A shared pharmacy service can result in an improved element of drug use control for smaller hospitals in a cost-effective manner.

Cost-Benefit Analysis↗

DTIC, CCNU, bleomycin and vincristine (BOLD) in metastatic melanoma.

Treatment of 91 consecutive patients having metastatic, Stage IV melanoma who had not received any previous chemotherapy was begun between January 1977 and April 1978. The therapy included bleomycin (B) at 7.5 units subcutaneously in the first course and 15 units in subsequent courses on days 1 and 4; vincristine or Oncovin (O) at 1 mg/m2 intravenously on days 1 and 5; CCNU or lomustine (L) at 80 mg/m2 p.o. on day 1 and DTIC (D) 200 mg/m2 intravenously on days 1 through 5. Evaluable patients (72) were those who had measurable tumours in the viscera and on the skin. Seven patients (9%) responded with complete tumor regression (CR), 22 (31%) with partial regression (PR) (50% or more tumor regression), 12 (17%) with stabilization of disease, and 31 (43%) with progression of the disease. Patients who responded with CR, PR, and stable disease (41 patients) had a median survival of 67 weeks, while those who did not respond (31 patients) had a median survival of 20 weeks (P < .0001). Overall median survival was 31 weeks. The bleomycin-Oncovin-lomustine-DTIC (BOLD) regimen is an effective alternative treatment for metastatic melanoma; there is good tumor response and prolongation of survival in the responding patients. Its overall toxicity is mild to moderate.

Antineoplastic Agents↗